Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

November 21, 2014

Primary Completion Date

December 29, 2017

Study Completion Date

December 29, 2017

Conditions
Polycythemia Vera
Interventions
DRUG

Ruxolitinib

supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally

Trial Locations (65)

1070

Novartis Investigative Site, Brussels

1413

Novartis Investigative Site, Sofia

1431

Novartis Investigative Site, Sofia

2060

Novartis Investigative Site, Antwerp

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Liège

4002

Novartis Investigative Site, Plovdiv

5020

Novartis Investigative Site, Salzburg

5530

Novartis Investigative Site, Yvoir

5800

Novartis Investigative Site, Pleven

8000

Novartis Investigative Site, Bruges

9038

Novartis Investigative Site, Tromsø

10400

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

13273

Novartis Investigative Site, Marseille

13357

Novartis Investigative Site, Berlin

22081

Novartis Investigative Site, Hamburg

31059

Novartis Investigative Site, Toulouse

33076

Novartis Investigative Site, Bordeaux

40002

Novartis Investigative Site, Khon Kaen

46236

Novartis Investigative Site, Bottrop

49033

Novartis Investigative Site, Angers

50200

Novartis Investigative Site, Chiang Mai

54511

Novartis Investigative Site, Vandœuvre-lès-Nancy

56068

Novartis Investigative Site, Koblenz

57000

Novartis Investigative Site, Metz

59063

Novartis Investigative Site, Hamm

60389

Novartis Investigative Site, Frankfurt

60596

Novartis Investigative Site, Frankfurt

63739

Novartis Investigative Site, Aschaffenburg

64000

Novartis Investigative Site, Monterrey

64109

Novartis Investigative Site, Bayonne

65812

Novartis Investigative Site, Bad Soden

66046

Novartis Investigative Site, Perpignan

68070

Novartis Investigative Site, Mulhouse

68305

Novartis Investigative Site, Mannheim

69115

Novartis Investigative Site, Heidelberg

70376

Novartis Investigative Site, Stuttgart

72037

Novartis Investigative Site, Le Mans

73011

Novartis Investigative Site, Chambéry

73557

Novartis Investigative Site, Mutlangen

74072

Novartis Investigative Site, Heilbronn

74374

Novartis Investigative Site, Pringy

75010

Novartis Investigative Site, Paris

77104

Novartis Investigative Site, Meaux

84902

Novartis Investigative Site, Avignon

86150

Novartis Investigative Site, Augsburg

88045

Novartis Investigative Site, Friedrichshafen

91054

Novartis Investigative Site, Erlangen

94805

Novartis Investigative Site, Villejuif

97080

Novartis Investigative Site, Würzburg

99817

Novartis Investigative Site, Eisenach

2540364

Novartis Investigative Site, Viña del Mar

8420383

Novartis Investigative Site, Santiago

A-4010

Novartis Investigative Site, Linz

A 4600

Novartis Investigative Site, Wels

V5Z 1M9

Novartis Investigative Site, Vancouver

L8V 5C2

Novartis Investigative Site, Hamilton

Unknown

Novartis Investigative Site, Santiago

06202

Novartis Investigative Site, Nice

NO-1603

Novartis Investigative Site, Fredrikstad

1099 023

Novartis Investigative Site, Lisbon

1749-035

Novartis Investigative Site, Lisbon

SE 971 80

Novartis Investigative Site, Luleå

451 80

Novartis Investigative Site, Uddevalla

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY